Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 5MB, 226 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 80 results:
Author Title [ Type(Asc)] Year
Filters: Author is Azoulay, L.  [Clear All Filters]
Journal Article
A. Douros, Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., and Azoulay, L., “Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy”, Diabetes Care, vol. 41, pp. 2330-2338, 2018.
J. L. Faillie, Filion, K. B., Patenaude, V., Ernst, P., and Azoulay, L., “Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes”, Diabetes Obes Metab, vol. 17, pp. 379-85, 2015.
A. Douros, Rouette, J., Yin, H., Yu, O. H. Y., Filion, K. B., and Azoulay, L., “Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes”, Diabetes Care, 2019.
D. Abrahami, Douros, A., Yin, H., Yu, O. H. Y., Renoux, C., Bitton, A., and Azoulay, L., “Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study”, Bmj, vol. 360, p. k872, 2018.
R. Pradhan, Abrahami, D., Yin, H., Yu, O. H. Y., Sahasrabudhe, V., E. Andre, B., and Azoulay, L., “Defining Clinically-Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials”, Clin Pharmacol Ther, 2021.
L. Azoulay, Dell'Aniello, S., Huiart, L., Fort, G. G. du, and Suissa, S., “Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence”, Breast Cancer Res Treat, vol. 126, pp. 695-703, 2011.
F. Lapi, Azoulay, L., Yin, H., Nessim, S. J., and Suissa, S., “Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study”, Bmj, vol. 346, p. e8525, 2013.
L. Azoulay, Dell'Aniello, S., Simon, T., Renoux, C., and Suissa, S., “The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation”, Thromb Haemost, vol. 109, pp. 431-9, 2013.
L. Azoulay, Schneider-Lindner, V., Dell'Aniello, S., Schiffrin, A., and Suissa, S., “Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study”, Pharmacoepidemiol Drug Saf, vol. 19, pp. 335-42, 2010.
O. H. Yu, Yin, H., and Azoulay, L., “The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death”, Can J Diabetes, vol. 39, pp. 383-9, 2015.
S. Y. Loo, Azoulay, L., Nie, R., Dell'Aniello, S., Yu, O. H. Y., and Renoux, C., “Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study.”, Am J Med, 2019.
F. Khosrow-Khavar, Bouganim, N., Filion, K. B., Suissa, S., and Azoulay, L., “Cardiotoxicity of Sequential Aromatase Inhibitors Use in Women with Breast Cancer”, Am J Epidemiol, 2020.
S. Couraud, Azoulay, L., Dell'Aniello, S., and Suissa, S., “Cardiac glycosides use and the risk of lung cancer: a nested case-control study”, BMC Cancer, vol. 14, p. 573, 2014.
S. Couraud, Dell'Aniello, S., Bouganim, N., and Azoulay, L., “Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia”, Breast Cancer Res Treat, vol. 146, pp. 619-26, 2014.
J. L. Faillie, Yu, O. H., Yin, H., Hillaire-Buys, D., Barkun, A., and Azoulay, L., “Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus”, JAMA Intern Med, vol. 176, pp. 1474-1481, 2016.
D. Abrahami, Renoux, C., Yin, H., Fournier, J. P., and Azoulay, L., “The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation”, Thromb Haemost, 2020.
F. Khosrow-Khavar, Yin, H., Barkun, A., Bouganim, N., and Azoulay, L., “Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer”, Ann Oncol, vol. 29, pp. 744-748, 2018.
F. Khosrow-Khavar, Filion, K. B., Bouganim, N., Suissa, S., and Azoulay, L., “Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study”, Circulation, vol. 141, pp. 549-559, 2020.
B. M. Hicks, Filion, K. B., Yin, H., Sakr, L., Udell, J. A., and Azoulay, L., “Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study”, Bmj, vol. 363, p. k4209, 2018.
L. Azoulay, Yin, H., Benayoun, S., Renoux, C., Boivin, J. F., and Suissa, S., “Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer”, Eur Urol, vol. 60, pp. 1244-50, 2011.
A. J. Klil-Drori, Yin, H., Tagalakis, V., Aprikian, A., and Azoulay, L., “Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism”, Eur Urol, vol. 70, pp. 56-61, 2016.
B. M. Hicks, Yin, H., Bladou, F., Ernst, P., and Azoulay, L., “Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia”, Thorax, vol. 72, pp. 596-597, 2017.
A. J. Klil-Drori, Santella, C., Tascilar, K., Yin, H., Aprikian, A., and Azoulay, L., “Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study”, Drug Saf, 2019.
F. Khosrow-Khavar, Rej, S., Yin, H., Aprikian, A., and Azoulay, L., “Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer”, J Clin Oncol, vol. 35, pp. 201-207, 2017.
J. Assayag, Yin, H., Benayoun, S., Pollak, M. N., Suissa, S., and Azoulay, L., “Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer”, Cancer Causes Control, vol. 24, pp. 839-45, 2013.
B. M. Hicks, Klil-Drori, A. J., Yin, H., Campeau, L., and Azoulay, L., “Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer”, Epidemiology, vol. 28, pp. 712-718, 2017.
A. J. Klil-Drori, Tascilar, K., Yin, H., Aprikian, A., Bitton, A., and Azoulay, L., “Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer”, Am J Epidemiol, vol. 184, pp. 15-22, 2016.
F. Lapi, Azoulay, L., Niazi, M. T., Yin, H., Benayoun, S., and Suissa, S., “Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer”, Jama, vol. 310, pp. 289-96, 2013.
G. Simoneau, Moodie, E. E. M., Azoulay, L., and Platt, R. W., “Adaptive Treatment Strategies with Survival Outcomes: An Application to the Treatment of Type 2 Diabetes using a Large Observational Database”, Am J Epidemiol, 2020.
L. Azoulay, Eberg, M., Benayoun, S., and Pollak, M., “5alpha-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer”, JAMA Oncol, vol. 1, pp. 314-20, 2015.
[Page last reviewed 6 April 2021]